We have a suspicion that you are an automated web bot software, not a real user. To keep our site fast for other users, we have slowed down this page. The slowdown will gradually disappear. If you think this is a mistake, please contact us at genome-www@soe.ucsc.edu. Also note that all data for hgGeneGraph can be obtained through our public MySQL server and all our software source code is available and can be installed locally onto your own computer. If you are unsure how to use these resources, do not hesitate to contact us.
UCSC Genome Browser Gene Interaction Graph
Gene interactions and pathways from curated databases and text-mining

◀ Back to MTOR

MTOR — PCNA

Text-mined interactions from Literome

Panwalkar et al., Cancer 2004 (Hematologic Neoplasms) : Inhibitors of mTOR also prevent cyclin dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which may help cause G1-phase arrest
Wing et al., J Biol Chem 2005 (MAP Kinase Signaling System) : Activation of mTOR by FGF9 induces p70 ribosomal S6 kinase ( S6K1 ) phosphorylation, cyclin expression, and cell proliferation, which are independent of phosphatidylinositol 3-kinase and Akt
Giles et al., Curr Mol Med 2005 (Hematologic Neoplasms...) : As a consequence of inhibiting its downstream messengers, mTOR inhibitors prevent cyclin dependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which may help cause GI phase arrest
Xu et al., Cancer Res 2006 (Prostatic Neoplasms) : DHT treatment increased mTOR activity as assessed by phosphorylation of the downstream targets p70 S6 kinase and 4E-BP1, and mTOR inhibition with rapamycin blocked the DHT stimulated increase in cyclin D proteins
Huang et al., Cancer Lett 2009 (Carcinoma...) : Also, we found blockage mTORC1 inhibited Cyclin D1 expression in CNE-2 cells and enhanced cell apoptosis
Coiffier et al., Leukemia & lymphoma 2009 (Hematologic Neoplasms...) : Mantle cell lymphoma ( MCL ) was the first hematologic malignancy in which mTOR inhibition was explored as a treatment strategy, owing to its characteristic overexpression of cyclin D1, a G1 cyclin regulated by mTOR signaling
Velazquez-Garcia et al., Diabetes 2011 (Glucose Intolerance) : Phosphorylation/inactivation of GSK-3ß and phosphorylation/activation of mTOR , critical regulators of D-cyclin expression and ß-cell proliferation, were enhanced in TG mouse islets, without changes in Akt phosphorylation status